Pharmacotherapies for diabetic retinopathy: Present and future

Research output: Contribution to journalReview articlepeer-review

32 Scopus citations


Diabetic retinopathy remains a major cause of worldwide preventable blindness. Measures to avoid blindness include medical management (control of blood sugar, blood pressure, and serum lipids) and ocular management (laser photocoagulation and pars plana vitrectomy). Adjunctive pharmacologic therapies (intravitreal triamcinolone acetonide and anti-vascular endothelial growth factor agents) have shown early promise in the treatment of both diabetic macular edema and proliferative diabetic retinopathy. Other medications under investigation include the fluocinolone acetonide implantable device, extended-release dexamethasone implant, oral ruboxistaurin, and intravitreal hyaluronidase.

Original languageEnglish (US)
Article number52487
JournalExperimental Diabesity Research
StatePublished - 2007
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pharmacotherapies for diabetic retinopathy: Present and future'. Together they form a unique fingerprint.

Cite this